Galectin Therapeutics Inc. (GALT)

Market Cap	181.49M +94.1%
Revenue (ttm)	n/a
Net Income	-37.44M
EPS	-0.59
Shares Out	64.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	398,991
Open	3.140
Previous Close	3.150
Day's Range	2.800 - 3.180
52-Week Range	1.120 - 7.130
Beta	1.02
Analysts	Strong Buy
Price Target	8.50 (+201.95%)
Earnings Date	Mar 31, 2026

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Ther...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT
• Website: https://galectintherapeutics.com

Analyst Summary

According to 3 analysts, the average rating for GALT stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 201.95% from the latest price.

Price Target

$8.5

(201.95% upside)

Analyst Consensus: Strong Buy